For patients with advanced melanoma without BRAF mutation who no longer respond to immune checkpoint inhibitors, treatment ...
Lung cancer cells are able to take advantage of a person’s immune system, specifically T cells, to protect the tumor, according to new research recently published in Cancer Immunology Research.
Cancer tumors hijack the vagus nerve to communicate with the brain, triggering a hormonal response that suppresses the immune system.
Researchers found that combining trametinib, rigosertib, and a CD40 agonist blocked immune-suppressive B cells and restored anti-PD-1 response in resistant melanoma models. The strategy could expand ...
A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune response in five preclinical models of head and neck cancer, according to ...
The tumor microenvironment (TME) consists of mediators surrounding a tumor, including diverse cell types, blood vessels, and other cellular components. Certain elements of the TME can benefit patients ...
A preclinical study by researchers at Baylor College of Medicine has uncovered a mechanism that allows triple-negative breast cancer (TNBC) to develop resistance to immune checkpoint blockade (ICB) ...
On the one hand, circadian rhythm disorder contributes to tumor growth and metastasis by influencing the dysregulation of gene expression affecting the tumor itself. On the other hand, circadian ...
A new DNA immunotherapy, Elenagen, doubled survival (13 to 25+ months) for tough ovarian cancers when added to chemotherapy, with fewer side effects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results